-
08 October 2025
-
08 October 2025
Ipsen to present data across five rare liver diseases at AASLD 2025
Paris, France – October 8, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 13 scientific abstracts at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). The abstracts spa...
-
06 May 2025
-
06 May 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
PARIS, FRANCE, 6 May 2025 – Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced that seven abstracts with new data from its rare liver disease portfolio will be presented at the European Association for the Study of the Liver (EASL) congress, 7 – 10 May...
-
08 October 2025
-
08 October 2025
Ipsen présentera des données sur cinq maladies rares du foie lors du congrès de l’AASLD 2025
Paris, France – 8 octobre, 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui la présentation de 13 résumés scientifiques lors du congrès The Liver Meeting® 2025, organisé par l’American Association for the Study of Liver Dis...
-
30 January 2026
-
30 January 2026
Ipsen expands pre-clinical pipeline in rare neurodegenerative diseases
PARIS, FRANCE 30 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today a new global collaboration and option agreement with Origami Therapeutics for a research stage protein degrader program targeting genetic neurodegenerative diseases. Followin...
-
06 May 2025
-
06 May 2025
Ipsen présentera de nouvelles données sur quatre maladies rares du foie au Congrès EASL, y compris des données « Late Breaking » dans la CBP et la CSP
Paris (France), 6 mai 2025 – Ipsen (Euronext : IPN ; ADR : (IPSEY) a annoncé aujourd’hui que sept abstracts présentant de nouvelles données dans son portefeuille de médicaments en maladies rares du foie seront exposés lors du congrès de l’Ass...
-
09 June 2026
-
09 June 2026
Ipsen welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)
PARIS, FRANCE, 9 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today welcomes the publication of the European Union’s (EU) Joint Clinical Assessment (JCA) report for Ojemda® (tovorafenib) for the treatment of patients with relapsed or refractory BRAF-al...
-
09 January 2026
-
09 January 2026
Ipsen Statement on Lanreotide Generic Supply Challenges
Attachment...
-
03 October 2024
-
03 October 2024
An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024. ...
-
03 October 2024
-
03 October 2024
Nouvelle information importante à l’attention des professionnels de santé et des patients concernant la solution injectable Increlex® (mécasermine)
Ce médicament essentiel, ainsi que toutes les activités associées, vont être transférés à Eton Pharmaceuticals à la suite de la signature d’un accord de transfert d’actif, qui devrait être conclu à la fin de l’année 2024....
-
06 June 2023
-
06 June 2023
Ipsen and Medetia join forces to accelerate early research in rare disease
In keeping with Ipsen’s drive to accelerate the research and development of transformative therapies, we are pleased to announce a new research collaboration agreement with Medetia, a biotech with extensive drug discovery and medicinal chemistry exp...